Kornimate/medical-research-clean huggingface dataset:
proton radiation therapy with cisplatin and etoposide followed by surgery in stage iii non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: this research study is looking at an alternative way of delivering radiation therapy with protons. protons are tiny particles with a positive charge that can be controlled to travel a certain distance and stop inside the body. in theory, this allows better control of where the radiation dose is delivered as compared to photons. information from other research studies suggests that proton radiation may help to reduce unwanted side effects from radiation and allow an increase in radiation dose that increase the odds of tumor killing. the purpose of this study is to determine the safest dose of proton radiation therapy to give in combination with standard chemotherapy in participants with non-small cell lung cancer (nsclc).

proton radiation will be delivered daily monday through friday for 5 weeks. study therapy will be give as an outpatient at the francis h. burr proton center at massachusetts general hospital. during the weeks that subjects receive radiation, they will also receive 2 cycles of chemotherapy. each cycle will last 28 days. cisplatin will be give as an iv infusion over 30-60 minutes or 1-2 hours on days 1 and 8 of cycles 1 and 2. etoposide will be given as an iv infusion over 60 minutes on days 1, 2, 3, 4, 5 of cycles 1 and 2. after radiation and 2 cycles of chemotherapy are completed, subjects may have surgery to remove their tumor. following surgery, subjects may receive another 2 cycles of chemotherapy (cycles 3 and 4). each cycles lasts 21 days. cisplatin is given on day 1. etoposide is given on days 1, 2, and 3.

Eligibility criteria:
inclusion criteria: * histologically confirmed non-small cell lung cancer with a clinical stage of iiia * candidate for chemoradiation and surgical resection * measurable disease * life expectancy \> 6 months * normal organ and marrow function exclusion criteria: * pregnant or breast-feeding * prior therapy for lung cancer with chemotherapy * prior chest radiation * compromised pulmonary function * severe neurovascular disease * history of high cardiac risk including unstable angina * history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin or etoposide * uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive hear failure, unstable angina pectoris, clinically significant or serious cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * history of a different malignancy unless disease-free for at least 3 years and at low risk for recurrence. individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, non muscle-invasive bladder cancer, basal cell or squamous cell carcinoma of the skin * subjects with hiv

Keywords: lung cancer stage iii
optimisation of potential dental implant sites protection for rehabilitation in patients with head and neck cancer: impact of virtual implants visualisation on dosimetry (oppidom)

Conditions: Squamous Cell Carcinoma of Head and Neck; Oropharyngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma

Summary: this is a monocentric, non-randomized, prospective, in silico feasibility study conducted by strasbourg europe cancerology institute. the purpose of this study is to evaluate the optimisation of potential dental implant sites protection, without degrading tumor volume coverage, through designation of potential dental implant sites before volume delineation and dosimetry calculations in patients with oropharyngeal or oral cavity squamous cell carcinoma treated by radiotherapy.

35 patients will be included in this study and will benefit from a dental consultation for dental rehabilitation plan elaboration and radiological guide confection. two dosimetric computer-tomography scans, with or without radiological guide, will be conducted. virtual dental implants will be visualised by the dental surgeon on scanner images (with or without radiologic guide). after volume delineation and dosimetry calculations, the optimal treatment plan will be validated. patients will be followed throughout radiotherapy and during 18 months following the end of radiotherapy for evaluation of toxicity, quality of life and dental implant survival rate.

Eligibility criteria:
inclusion criteria: * patients must be ≥ 18 years old * performance status 0 to 2 * histologically-confirmed diagnosis of : infiltrating squamous cell carcinoma of the oral cavity or oropharynx * indication for an exclusive radiotherapy or post-surgery radiotherapy, with or without chemotherapy * indication for a radiotherapy of lymph node areas * partial or complete toothlessness requiring rehabilitation * signed informed consent from the patient exclusion criteria: * history of head and neck radiotherapy * partial mandibulectomy * retarded wound healing or trismus impairing radiological guide preparation * patient refusing the study * pregnant women

Keywords: radiotherapy head and neck cancer
entecavir plus tenofovir combination therapy versus entecavir monotherapy in naive subjects with chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: the purpose of this study is to compare the effectiveness of entecavir plus tenofovir combination therapy with that of entecavir monotherapy. safety will also be studied.


Eligibility criteria:
inclusion criteria: * chronic hepatitis b virus (hbv) infection (hepatitis b e antigen \[hbeag\]-positive or negative) disease * nucleoside- and nucleotide-naive * males or females ≥16 years of age (or minimum age of consent in a given country) * compensated liver function * hbv dna \>1.72\*10\*5\*iu/ml (approximately 10\*6\*copies/ml) for hbeag-positive participants * hbv dna \>1.72\*10\*4\*iu/ml (approximately 10\*5\*copies/ml) for hbe-ag-negative participants * alanine aminotransferase level ≥\*upper limit of normal (uln) and ≤10\*uln exclusion criteria: * evidence of decompensated cirrhosis * coinfection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus * laboratory values out of protocol-specified range
eu sites: fluid management of acute decompensated heart failure with reprieve decongestion management system (fastr-eu)

Conditions: Acute Decompensated Heart Failure

Summary: the objective of this study is to prospectively compare decongestive therapy administered by the reprieve dms system to optimal diuretic therapy (odt) in the treatment of patients diagnosed with acute decompensated heart failure (adhf). the main objective is to determine if the reprieve dms is non-inferior to state-of-the-art urine sodium guided aggressive diuretic titration in two european hf centers of excellence.


Eligibility criteria:
inclusion criteria: 1. hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom and 1 sign. 2. ≥10 pounds (4.5 kg) above dry weight either by historical weights or as estimated by health care provider. 3. prior use of loop diuretics within 30 says prior to admission. 4. ≥ 18 years of age able to provide informed consent and comply with study procedures. exclusion criteria: 1. inability to place foley catheter or iv catheter. 2. hemodynamic instability. 3. dyspnea due primarily to non-cardiac causes. 4. acute infection with evidence of systemic involvement. 5. estimated glomerular filtration rate (egfr) \< 20 ml/min/1.73m2 calculated using the mdrd equation or current use of renal replacement therapy. 6. significant left ventricular outflow obstruction, uncorrected complex congenital heart disease, severe stenotic valvular disease, infiltrative or constrictive cardiomyopathy, acute myocarditis, type 1 acute myocardial infarction requiring treatment, or any other pathology that, in the opinion of the investigator, would make aggressive diuresis poorly tolerated. 7. inability to follow instructions or comply with follow-up procedures. 8. other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures. 9. severe electrolyte abnormalities. 10. presence of active coronavirus disease 2019 (covid-19) infection. 11. enrollment in another interventional trial during the index hospitalization. 12. inability to return for follow-up study visits. 13. life expectancy less than 3 months. 14. women who are pregnant or intend to become pregnant.
international bpa registry

Conditions: Chronic Thromboembolic Pulmonary Hypertension; CTEPH

Summary: the international balloon pulmonary angioplasty (bpa) registry is a prospective, multi-center, long-term observational project. scheduled to start data collection in q4 2017, the registry will run for approximately four years with a follow-up time for each patient of at least two years. its primary objective is to investigate the efficacy and safety of bpa intervention in patients with chronic thromboembolic pulmonary hypertension (cteph) not amenable to pulmonary endarterectomy (pea).


Eligibility criteria:
inclusion criteria: * diagnosis with cteph according to the following criteria: * mean pap ≥ 25mmhg at rest; or if mean pap \< 25mmhg at rest, have exercise limitations from chronic thromboembolic disease * abnormal ventilation perfusion lung scanning (vq) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines * treatment with anticoagulation for ≥ 3 months before diagnosis of cteph * naïve to bpa treatment * scheduled to undergo their first bpa session ≥ 1 day after enrollment. enrollment is defined as date the consent is signed by the patient. enrollment must occur before any bpa session * willing to provide informed consent exclusion criteria: * bpa treatment prior to enrollment * pulmonary hypertension cause other than world health organization (who) group iv (cteph) * targeted bpa treatment lesion other than from who group iv (cteph)

Keywords: balloon pulmonary angioplasty bpa
risk of aspergillus infection in patients with chronic lung disease

Conditions: Fungal Infection Lungs

Summary: large doses of systemic corticosteroids ，severe lung tissue damage and longer copd diagnosis may increase the risk of ipa in patients with chronic structural lung disease. by comparing the risk factors of aspergillus colonization group and aspergillus infection group, the main risk factors of aspergillus pneumonia were determined.

patients with chronic lung disease were identified as positive for aspergillus fumigatus through sputum microscopy. according to diagnostic criteria, patients diagnosed with ipa and cpa and were assigned to the aspergillosis pneumonia group, while the remaining patients were included in the aspergillus colonization group. then,risk factors for aspergillus pneumonia, invasive pulmonary aspergillus disease, and chronic pulmonary aspergillus disease, such as the use of high-dose corticosteroids, inhaled corticosteroids, and the extent of damage to basic lung structures, were identified by comparing the aspergillus colonization group with the aspergillus infection group.

Eligibility criteria:
inclusion criteria: 1. age : at least 18 years old ; 2. imageological examination : patients who complete high-resolution computed tomography (hrct) images of the chest; 3. serological examination : patients who complete serological test results, including serum aspergillus specific igg antibody, serum aspergillus igm antibody and gm antigen detection. exclusion criteria: 1. immunodeficiency conditions : patients diagnosed with hiv infection, hematological malignancies, and autoimmune diseases. 2. critically ill patients : those who require mechanical ventilation in the icu and have established various types of cardiopulmonary bypass. 3. inadequate clinical data: inability to provide reliable diagnostic measurements or insufficient clinical information.
dose escalation for sbrt of recurrent vt ventricular tachyarrhythmia - a single center, phase ii clinical trial

Conditions: Ventricular Tachycardia

Summary: the objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of vt treatment and therefore dose-escalation will lead to a significantly reduced long-term vt recurrence rate compared to the currently applied single dose of 25 gy.


Eligibility criteria:
inclusion criteria: patients with structural heart disease, in particular ischemic and non-ischemic cardiomyopathy: implanted icd and/or crt-d. prior ≥1 failed catheter ablation (with endocardial ± epicardial approach based on the substrate location and the ecg morphology of clinical vts) procedure to control sustained monomorphic vt using currently recommended mapping and ablation techniques,2 or patients in whom ablation is not feasible. reasons for lack of epicardial ablation and non-feasibility of catheter ablation must be specified. sustained vt recurrence after catheter ablation on optimised antiarrhythmic medication. age ≥18 years. irb-approved, written informed consent must be provided exclusion criteria: patients with only premature ventricular contractions. patients with sustained vt/vf who demonstrate: acute myocardial infarction; primary electrical disease (channelopathy); reversible and treatable cause (e.g., drug-induced or intoxication) of vt that can be adequately addressed otherwise; a target that cannot be safely and precisely defined based on stereotactic radiotherapy accuracy requirements (e.g., anatomical interference from oars, overlapping prior radiation therapy to the thoracic region); pregnancy or breastfeeding; inability to provide informed consent.
lepticore in metabolic syndrome and weight loss

Conditions: Obesity; Hyperlipidemia; Hyperglycemia

Summary: metabolic syndrome is directly related to obesity. this study investigated the use of a plant based formulation to improve on the condition of people with metabolic syndrome.

lepticore is a proprietary combination of various ingredients which have been shown to have properties which could be beneficial to weight loss in obese and overweight human subjects. this study evaluates the effect of lepticore on bodyweight as well as parameters associated with obesity and metabolic syndrome. the study was an 8 week randomized, double-blind, placebo-controlled design involving 92 obese (mean bmi\>30kg/m2) participants (37 males; 55 females; ages 19-52; mean age = 30.7). the participants were randomly divided into three groups: placebo (n=30), lepticore formula a (low dose) (n=31) and lepticore formula b (high dose) (n=31). capsules containing the placebo or active formulations were administered twice daily before meals with 300 ml of water. none of the participants followed any specific diet nor took any weight-reducing medications for the duration of the study. a total of 12 anthropomorphic and serological measurements were taken at the beginning of the study and after 2, 4, 6, and 8 weeks of treatment.

Eligibility criteria:
inclusion criteria: * bmi \>30 kg/m2 * total cholesterol \>200 mg/dl * ldl cholesterol \>160 mg/dl * hdl cholesterol \ 150 mg/dl * fasting blood glucose \>100 mg/dl * blood pressure \>130/85 mmhg. exclusion criteria: * morbid obesity (bmi \>40 kg/m2 ) * diabetes mellitus requiring daily insulin management * pregnancy/lactation * active infection * systemic disease such as hiv/aids, * use of any cholesterol-lowering medications 30 days prior to study * enrollment in another clinical study within the past 6 months.

Keywords: obesity metabolic syndrome c-reactive protein leptin
effect of exercise among turtle neck syndrome in pakistani patients

Conditions: Neck Pain

Summary: turtle neck also known as text neck or anterior head syndrome is an overuse syndrome which occurs due to repetitive stress to neck, either by hanging it down or forward using phone or electronic devices. typical signs and symptoms include pain and stiffness in the neck, shoulder pain and increase curvature of spine. it is becoming a global burden as people of almost all ages are getting affected. the objective of the study is to find out theeffect of exercise among turtle neck syndrome in pakistani population. a total of 100 participants will be included in the study having both males and females. the pain pattern will be assessed by visual analog scale and posture grid assessment tool will be used to assess posture before and after the treatment session. the study will be divided into three main sections or groups. one group will be treated by myofascial release only while other group will be treated by muscle energy technique for the management of turtle neck syndrome. third group will receive both mfp and met exercise. people having neck pain and those who will be willing to participate will be included in the study.

the participants will be divided into four groups namely group a, b, c and d. initially all the participants will be assessed by posture grid assessment tool to check their postural deviations. people meeting the inclusion criteria will be recruited. group a will receive muscle energy technique (met) exercise, group b will receive myofascial release (mfp) therapy, group c will receive both mfp and met and group d will receive conventional treatment. pre and post visual analog scale (vas) will be used to check pain scale and posture grid assessment tool to check postural angles .pre-assessment will be done on day one and post at the last day of session. the total duration of treatment will be four weeks. consent will be taken from the patients. only those patients meeting the inclusion criteria and screening questions will included in the study and those who will be willing to participate.

Eligibility criteria:
inclusion criteria: * both males and females will be included * patients having non specific neck pain * usage of mobile more than six hours * patients willing to participate exclusion criteria: * pregnant females * patients having cervical disc bulge or herniation disoriented patients * patients not willing to participate * patients having any deformity

Keywords: text neck syndrome neck pain turtle neck syndrome tissue hardness pain pressure threshold
post-intensive care follow-up of patients hospitalized for an acute respiratory distress syndrome caused by covid-19

Conditions: Human ARDS; Coronavirus Infection

Summary: for the last years, studies have described the " post-intensive care syndrome " (pics), which consists in alteration of quality of life, cognition, autonomy and psychological disorders within the months after intensive-care. patients with covid-19 in intensive care units are at high risks to develop pics. the primary objective is to analyse the incidence of the post-traumatic stress disorder at 12 months after intensive-care for a covid-19 acute respiratory distress syndrome (ards).

many studies have showed that ards survivors keep, even a long time after hospitalization, a functional respiratory disability, resulting on one hand from impaired diffusion of carbon monoxide, and on the other hand from a muscular weakness. indeed, 67% of patients ventilated more than 10 days have a neuromyopathy whose recovery is uncertain. beside this, long-term quality of life is worse than in general population, due in particular to depressive and anxiety disorders such as post-traumatic syndrome disorder with a prevalence around 22% after one year. the follow-up will consist in phone call with an intensive care doctor. these visits would be the opportunity to screen the complications after intensive-care with, find solutions to cure them or decrease their impact on patient's life to improve quality of life and prevent the post-traumatic syndrome disorder ptsd. a review would be sent to the patients' general practitioners at the end of each visit.

Eligibility criteria:
inclusion criteria: * adult patient * hospitalized in intensive care of the chu anesthesia-intensive care unit (rangueil, urm, neurosurgery) * intubated and ventilated * supported for an ards according to the berlin criteria (pao2 / fio2 ratio \<300 mmhg) * with an rt-pcr positive to sars-cov-2 * affiliated to the french social security exclusion criteria: * minor patient * patient under protective measure * ards in the pandemic context but rt-pcr negative to sars-cov-2

Keywords: post-intensive care syndrome acute respiratory distress syndrome quality of life intensive care unit ptsd follow-up after icu covid-19
criteria used by health professionals on the selection of allergen immunotherapy in real clinical practice

Conditions: Allergen Immunotherapy

Summary: background : allergen immunotherapy (ait) is the only etiological treatment for allergic respiratory diseases. in order to improve the competence on the use of ait, it is important to extend the investigator's knowledge on its use in routine clinical practice, outside the experimental setting of clinical trials, in real life population of patients receiving ait. objective: to evaluate the clinical criteria used by treating clinicians and by the patients themselves, when establishing ait as treatment in a patient with respiratory disease caused by an ige-dependent-hypersensitivity to aeroallergens methods: in 6 country (denmark, france, germany, norway, spain \& sweden), the national coordinator will be directly responsible for selection of survey doctor's participants (investigators). during 12 months: * firstly, each investigator will complete the survey doctor, online, on surveymonkey platform to explain what are the key drivers in allergen immunotherapy (ait) selection (doctors' questionnaire, dq). * on the other hand, at each ait prescription to a patient, doctors will complete the survey patient, on the same platform, to explain how and why they have chosen this type of ait (patients' questionnaire, pq).


Eligibility criteria:
inclusion criteria: * patients with ige mediated respiratory allergy * patients who will initiate any type of aeroallergen ait according to real life clinical standards of practice * any type of aeroallergen for ait will be included : pollen, house dust mite, animal, dander, moulds * patient who is under the care of the doctor participating in the survey exclusion criteria: * patients who refuse to give their informed consent * food immunotherapy * venom immunotherapy

Keywords: immunotherapy real clinical practice respiratory disease aeroallergens ige-dependent hypersensitivity